Patents by Inventor Mark E. Duggan

Mark E. Duggan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Integrin antagonists
    Patent number: 6017925
    Abstract: This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. The vitronectin receptor antagonist compounds of the present invention are .alpha.v.beta.3 antagonists, .alpha.v.beta.5 antagonists or dual .alpha.v.beta.3/.alpha.v.beta.5 antagonists useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, viral disease, and tumor growth.
    Type: Grant
    Filed: January 13, 1998
    Date of Patent: January 25, 2000
    Assignee: Merck & Co., Inc.
    Inventor: Mark E. Duggan
  • Integrin receptor antagonists
    Patent number: 6017926
    Abstract: The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5 and/or .alpha.v.beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, and tumor growth and metastasis.
    Type: Grant
    Filed: December 15, 1998
    Date of Patent: January 25, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Ben C. Askew, Paul J. Coleman, Mark E. Duggan, Wasyl Halczenko, John H. Hutchinson, Robert S. Meissner, Michael A. Patane, Jiabing Wang
  • Integrin antagonists
    Patent number: 5981546
    Abstract: This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. The vitronectin receptor antagonist compounds of the present invention are .alpha.v.beta.3 antagonists, .alpha.v.beta.5 antagonists or dual .alpha.v.beta.3/.alpha.v.beta.5 antagonists useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation and tumor growth.
    Type: Grant
    Filed: August 18, 1997
    Date of Patent: November 9, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Duggan, George D. Hartman, William F. Hoffman, Robert S. Meissner, James J. Perkins, Ben C. Askew, Paul J. Coleman, John H. Hutchinson, Adel M. Naylor-Olsen
  • Integrin receptor antagonists
    Patent number: 5952306
    Abstract: Fibrinogen receptor antagonists having the formula ##STR1## for example ##STR2## which are useful for inhibiting the binding of fibrinogen to blood platelets and for inhibiting the aggregation of blood platelets.
    Type: Grant
    Filed: January 14, 1997
    Date of Patent: September 14, 1999
    Assignee: Merck & Co., Inc.
    Inventors: George D. Hartman, Mark E. Duggan, James J. Perkins, Cecilia A. Hunt, Amy E. Krause, John H. Hutchinson, Benny C. Askew, Karen M. Brashear, Nathan C. Ihle
  • Integrin antagonists
    Patent number: 5952341
    Abstract: This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. The vitronectin receptor antagonist compounds of the present invention are .alpha.v.beta.3 antagonists, .alpha.v.beta.5 antagonists or dual .alpha.v.beta.3/.alpha.v.beta.5 antagonists useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation and tumor growth.
    Type: Grant
    Filed: October 28, 1997
    Date of Patent: September 14, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Duggan, George D. Hartman
  • Guainidino, formamidino, amino and related compounds for inhibiting osteoclast-mediated bone resorption
    Patent number: 5929120
    Abstract: Compounds of the following general structureX--Y--Z-Aryl-A--B, ##STR1## which inhibit osteoclast mediated bone resorption.
    Type: Grant
    Filed: January 30, 1998
    Date of Patent: July 27, 1999
    Assignee: Merck & Co., Inc.
    Inventors: George D. Hartman, Mark E. Duggan, William F. Hoffman, Nathan C. Ihle
  • .alpha..sub.v .beta..sub.3 antagonists
    Patent number: 5925655
    Abstract: This invention relates to certain novel isoindolone compounds and derivatives thereof, their synthesis, and their use as .alpha.v.beta.3 receptor antagonists. The .alpha.v.beta.3 receptor antagonist compounds of this invention are useful for inhibiting bone resorption, treating and preventing osteoporosis and cancer, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation and tumor growth.
    Type: Grant
    Filed: April 8, 1997
    Date of Patent: July 20, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Duggan, George D. Hartman, William F. Hoffman
  • Integrin antagonists
    Patent number: 5919792
    Abstract: This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. The vitronectin receptor antagonist compounds of the present invention are .alpha.v.beta.3 antagonists, .alpha.v.beta.5 antagonists or dual .alpha.v.beta.3/.alpha.v.beta.5 antagonists useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation and tumor growth.
    Type: Grant
    Filed: October 28, 1997
    Date of Patent: July 6, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Duggan, George D. Hartman, William F. Hoffman, Nathan C. Ihle
  • Sulfonamide fibrinogen receptor antagonists
    Patent number: 5880136
    Abstract: A series of non-peptide derivatives that are antagonists of the fibrinogen IIb/IIIa receptor and thus are platelet anti-aggregation compounds useful in the prevention and treatment of diseases caused by thrombus formation.
    Type: Grant
    Filed: August 6, 1998
    Date of Patent: March 9, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Duggan, Melissa S. Egbertson, Wasyl Halczenko, George D. Hartman, William L. Laswell
  • Fibrinogen receptor antagonists
    Patent number: 5854245
    Abstract: Fibrinogen receptor antagonists having the structureX--Y--Z--A--Band pharmaceutically acceptable salts, wherein X is a 5, 6 or 7 membered aromatic or nonaromatic ring, and Y is a 5 or 6 membered aromatic ring, e.g.
    Type: Grant
    Filed: June 26, 1997
    Date of Patent: December 29, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Duggan, Melissa S. Egbertson, George D. Hartman, Steven D. Young, Nathan C. Ihle
  • Fibrinogen receptor antagonists
    Patent number: 5852045
    Abstract: Fibrinogen receptor antagonists having the structure, for example, of ##STR1## for example ##STR2##
    Type: Grant
    Filed: October 15, 1996
    Date of Patent: December 22, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Ben C. Askew, George D. Hartman, Mark E. Duggan, Steven D. Young, John H. Hutchinson, John S. Wai, Melissa S. Egbertson, Laura M. Vassallo, Laura A. Libby, Amy E. Krause, Wasyl Halczenko, Nathan C. Ihle
  • Sulfonamide fibrinogen receptor antagonists
    Patent number: 5814643
    Abstract: A series of non-peptide derivatives that are antagonists of the fibrinogen IIb/IIIa receptor and thus are platelet anti-aggregation compounds useful in the prevention and treatment of diseases caused by thrombus formation.
    Type: Grant
    Filed: May 22, 1997
    Date of Patent: September 29, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Duggan, Melissa S. Egbertson, Wasyl Halczenko, George D. Hartman, William L. Laswell
  • Fibrinogen receptor antagonists
    Patent number: 5786373
    Abstract: Novel fibrinogen receptor antagonists of the formula: X--Y--Z-Aryl-A--B and the pharmaceutically acceptable salts thereof, wherein Aryl is a 5-membered aromatic ring system containing 1 or 2 heteroatoms chosen from N, O or S wherein ring atoms may be unsubstituted or substituted with R.sup.5 and wherein S may be substituted with 0, 1 or 2 oxygen atoms; and X comprises various Nitrogen substituents including aromatic or nonaromatic systems; Y comprises, for example, alkyl or alkylaminocarbonylalkyl groups and Z and A are substituents which when present are independently chosen from alkyl or alkyloxyalkyl or other groups as defined herein; B is (a) or (b). The claimed compounds exhibit fibrinogen receptor antagonist activity, inhibit platelet aggregation and are therefore useful in modulating or preventing thrombus formation.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: July 28, 1998
    Assignee: Merck & Co., Inc.
    Inventors: George D. Hartman, John D. Prugh, Melissa S. Egbertson, Mark E. Duggan, William Hoffman
  • Fibrinogen receptor antagonists
    Patent number: 5780480
    Abstract: Fibrinogen receptor antagonists of the general formula:X-A-Y-Z-B Iand which includes, for example, the compounds of formula ##STR1## are useful for inhibiting the binding of fibrinogen to blood platelets, inhibiting the aggregation of blood platelets, treating thrombus formation or embolus formation, and preventing thrombus or embolus formation.
    Type: Grant
    Filed: February 26, 1997
    Date of Patent: July 14, 1998
    Assignee: Merck & Co., Inc.
    Inventors: John Wai, Thorsten E. Fisher, Mark E. Duggan, George D. Hartman, James J. Perkins
  • Pyridyl and naphthyridyl compounds for inhibiting osteoclast-mediated bone resorption
    Patent number: 5741796
    Abstract: Compounds of the following general structure X-Y-Z-Aryl-A-B, for example, ##STR1## which inhibit osteoclast mediated bone resorption. Specifically, the compounds are useful for treating mammals suffering from a bone condition caused or mediated by increased bone resorption, who are in need of such therapy. The compounds may be administered in oral dosage forms such as tablets, capsules, e.g. sustained release capsules, powders, granules, and suspensions.
    Type: Grant
    Filed: September 26, 1996
    Date of Patent: April 21, 1998
    Assignee: Merck & Co., Inc.
    Inventors: George D. Hartman, Mark E. Duggan, William F. Hoffman, Nathan C. Ihle
  • Sulfonamide fibrinogen receptor antagonists
    Patent number: 5658929
    Abstract: A series of non-peptide derivatives that are antagonists of the fibrinogen IIb/IIIa receptor and thus are platelet anti-aggregation compounds useful in the prevention and treatment of diseases caused by thrombus formation.
    Type: Grant
    Filed: July 21, 1995
    Date of Patent: August 19, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Duggan, Melissa S. Egbertson, Wasyl Halczenko, George D. Hartman, William L. Laswell
  • Fibrinogen receptor antagonists
    Patent number: 5648368
    Abstract: Novel fibrinogen receptor antagonists of the formula:X--Y--Z--Aryl--A--Bare provided in which the claimed compounds exhibit fibrinogen receptor antagonist activity, inhibit platelet aggregation and are therefore useful in modulating thrombus formation.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: July 15, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Melissa S. Egbertson, Laura M. Vassallo, George D. Hartman, Wasyl Halczenko, David B. Whitman, James J. Perkins, Amy E. Krause, Nathan Ihle, David Alan Claremon, William Hoffman, Mark E. Duggan
  • Fibrinogen receptor antagonists
    Patent number: 5559127
    Abstract: Fibrinogen receptor antagonists of the formula: ##STR1## wherein A,B,D,E,Y are as defined in the specification, are disclosed for use in inhibiting the binding of fibrinogen to blood platelets and for inhibiting the aggregation of blood platelets.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: September 24, 1996
    Assignee: Merck & Co., Inc.
    Inventors: George D. Hartman, John D. Prugh, Melissa S. Egbertson, Mark E. Duggan, William Hoffman, Wasyl Halezenko, Ben Askew
  • Fibrinogen receptor antagonists for inhibiting aggregation of blood platelets
    Patent number: 5455243
    Abstract: Fibrinogen receptor antagonists of the formula: ##STR1## such as ##STR2## are disclosed for use in inhibiting the binding of fibrinogen to blood platelets and for inhibiting the aggregation of blood platelets.
    Type: Grant
    Filed: December 20, 1993
    Date of Patent: October 3, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Duggan, Melissa S. Egbertson, Nathan Ihle, George D. Hartman, Laura M. Turchi, William F. Hoffman
  • Fibrinogen receptor antagonists
    Patent number: 5374622
    Abstract: A fibrinogen receptor antagonist of the formulaAc-Cys-Asn-Pro-(L-AMF)-Gly-Asp-Cys-OHorAc-Cys-Asn-(DiMeTzl)-(L-AMF)-Gly-Asp-Cys-OH.
    Type: Grant
    Filed: January 28, 1993
    Date of Patent: December 20, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Ruth F. Nutt, Stephen F. Brady, Daniel F. Veber, Mark E. Duggan